Two anti-CD33 monoclonal antibodies, Gemtuzumab Ozogamicin and Lintuzumab, were identified as promising repositioning candidates concerning Alzheimer’s disease (Fig. 4a). The gene discussed is CD33; the disease is early-onset autosomal dominant Alzheimer disease.